Teva launches AHZANTIVE, an Aflibercept biosimilar, across key European markets
Teva Pharmaceutical (NYSE:TEVA) announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea, across several major European markets, including France, Germany, Spain, and the Netherlands.


_1414334_640x360_2502483523615-640x360.webp&w=3840&q=75)

_1414328_640x360_2502504003560-640x360.webp&w=3840&q=75)
_1414328_640x360_2502480451940-640x360.webp&w=3840&q=75)
-640x360.webp&w=3840&q=75)




